.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Cerilliant
Moodys
US Army
Harvard Business School
Cipla
US Department of Justice
AstraZeneca
Fish and Richardson
Medtronic

Generated: November 24, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,889,185

« Back to Dashboard

Which drugs does patent 8,889,185 protect, and when does it expire?


Patent 8,889,185 protects ENVARSUS XR and is included in one NDA.

This patent has twenty-eight patent family members in fifteen countries.

Summary for Patent: 8,889,185

Title:Modified release compositions comprising tacrolimus
Abstract: A modified release composition comprising tacrolimus which is useful for the treatment or prevention of rejection reactions by transplantation of organs or tissues.
Inventor(s): Holm; Per (Vanlose, DK), Norling; Tomas (Lyngby, DK)
Assignee: Veloxis Pharmaceuticals A/S (Horsholm, DK)
Application Number:14/079,414
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form; Formulation;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Veloxis Pharms Inc
ENVARSUS XR
tacrolimus
TABLET, EXTENDED RELEASE;ORAL206406-001Jul 10, 2015RXYesNo► Subscribe► Subscribe PROPHYLAXIS OF ORGAN REJECTION
Veloxis Pharms Inc
ENVARSUS XR
tacrolimus
TABLET, EXTENDED RELEASE;ORAL206406-002Jul 10, 2015RXYesNo► Subscribe► Subscribe PROPHYLAXIS OF ORGAN REJECTION
Veloxis Pharms Inc
ENVARSUS XR
tacrolimus
TABLET, EXTENDED RELEASE;ORAL206406-003Jul 10, 2015RXYesYes► Subscribe► Subscribe PROPHYLAXIS OF ORGAN REJECTION
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 8,889,185

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Denmark2003 01232Aug 29, 2003
Denmark2003 01837Dec 11, 2003
Denmark2004 00079Jan 21, 2004
Denmark2004 00463Mar 23, 2004
Denmark2004 00467Mar 23, 2004

Non-Orange Book Patents for Patent: 8,889,185

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,994,214Solid dispersions comprising tacrolimus► Subscribe
8,591,946Modified release compositions comprising tacrolimus► Subscribe
8,617,599Modified release compositions comprising tacrolimus► Subscribe
8,889,186Modified release compositions comprising tacrolimus► Subscribe
8,623,411Modified release compositions comprising tacrolimus► Subscribe
9,161,907Modified release compositions comprising tacrolimus► Subscribe
9,763,920Solid dispersions comprising tacrolimus► Subscribe
9,757,362Modified release compositions comprising tacrolimus► Subscribe
8,623,410Modified release compositions comprising tacrolimus► Subscribe
8,586,084Modified release compositions comprising tacrolimus► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,889,185

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Norway337869► Subscribe
Norway20061430► Subscribe
Norway334986► Subscribe
China101869561► Subscribe
Germany602004028023► Subscribe
Denmark1663216► Subscribe
Denmark1663217► Subscribe
European Patent Office1663216► Subscribe
European Patent Office1663217► Subscribe
Spain2348640► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Argus Health
AstraZeneca
Novartis
US Army
Express Scripts
Dow
US Department of Justice
Deloitte
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot